✦ LIBER ✦

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours

✍ Scribed by Patrick Schöffski; Suzanne F. Jones; Herlinde Dumez; Jeffrey R. Infante; Elke Van Mieghem; Camilla Fowst; Paola Gerletti; Huiping Xu; John L. Jakubczak; Patricia A. English; Kristen J. Pierce; Howard A. Burris

Book ID: 116430847
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 215 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.07.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

A phase I dose escalation study of the p

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

✍ Edwina N. Scott; Anne L. Thomas; L. Rhoda Molife; Samreen Ahmed; Sarah Blagden; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 253 KB

Phase I safety, pharmacokinetic, and pha

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

✍ Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 362 KB

218 POSTER A phase I dose-escalation stu

218 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors

✍ E. Calvo; G. Edelman; J. Baselga; E. Kwak; C. Scheffold; L. Nguyen; G.I. Shapiro 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

The insulin-like growth factor-I recepto

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

✍ Molife, L R; Fong, P C; Paccagnella, L; Reid, A H M; Shaw, H M; Vidal, L; Arkena 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB